Rapidly-changing treatment landscapes in diseases like lung cancer pose challenges for medical education providers, who need to be more adaptable than ever.
Bristol-Myers Squibb’s hopes of adding a new indication to the label for S1P modulator Zeposia have been dented after the drug failed a phase 3 trial in Crohn’s disease.